Skip to main content

MorphoSys' AbD Serotec Unit to Provide Research Antibodies for Proteomika

NEW YORK (GenomeWeb News) — MorphoSys said today that Proteomika, a proteomics biomarker-discovery subsidiary of Progenika Biopharma, has ordered “multiple” research antibodies from its AbD Serotec business unit.
 
The agreement places Proteomika “among the largest customers for custom monoclonals services provided by AbD Serotec,” MorphoSys said, but did not disclose financial details.
Under the terms of the agreement, AbD Serotech will provide Proteomika with HuCal-based research antibodies against “a broad range of target molecules.”
 
Proteomika is involved in cancer-related in-house discovery projects at the bioGUNERResearch Institute, and has established research collaborations for non-invasive diagnostics, pharmacoproteomics markers, and novel therapeutic targets.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.